The estimated Net Worth of Carrie L. Bourdow is at least $1.65 Milione dollars as of 1 August 2022. Ms. Bourdow owns over 8,540 units of Trevena Inc stock worth over $74,398 and over the last 10 years she sold TRVN stock worth over $2,384. In addition, she makes $1,568,670 as President, Chief Executive Officer e Director at Trevena Inc.
Sign up
Ms. Bourdow TRVN stock SEC Form 4 insiders trading
Carrie has made over 4 trades of the Trevena Inc stock since 2016, according to the Form 4 filled with the SEC. Most recently she sold 8,540 units of TRVN stock worth $1,452 on 1 August 2022.
The largest trade she's ever made was buying 56,200 units of Trevena Inc stock on 28 June 2021 worth over $100,598. On average, Carrie trades about 1,879 units every 57 days since 2015. As of 1 August 2022 she still owns at least 9,933 units of Trevena Inc stock.
You can see the complete history of Ms. Bourdow stock trades at the bottom of the page.
Wallmine is a radically better financial terminal.
Sign up in seconds, it's free!
Wallmine is a radically better financial terminal.
Sign up in seconds, it's free!
Carrie Bourdow biography
Carrie L. Bourdow serves as President, Chief Executive Officer, Director of the Company. Ms. Bourdow has served as the President and Chief Executive Officer of our Company and member of our Board of Directors since October 2018. Prior to her role as Chief Executive Officer, she joined our company as our Chief Commercial Officer in May 2015 and was appointed Executive Vice President and Chief Operating Officer in January 2018. From May 2013 to May 2015, she was Vice President of Marketing at Cubist Pharmaceuticals, Inc. Prior to joining Cubist in 2013, Ms. Bourdow served for more than 20 years at Merck & Co., Inc., where she held positions of increasing responsibility across multiple therapeutic areas. Since June 2017 she has served as a member of the Board of Directors of Nabriva Therapeutics plc, a biopharmaceutical company, and she has served as a member of the Board of Directors of Sesen Bio, a biopharmaceutical company, since February 2020. Ms. Bourdow earned her B.A. from Hendrix College and her M.B.A. from Southern Illinois University.
What is the salary of Carrie Bourdow?
As the President, Chief Executive Officer e Director of Trevena Inc, the total compensation of Carrie Bourdow at Trevena Inc is $1,568,670. There are 1 executives at Trevena Inc getting paid more, with Maxine Gowen having the highest compensation of $2,808,860.
How old is Carrie Bourdow?
Carrie Bourdow is 57, she's been the President, Chief Executive Officer e Director of Trevena Inc since 2018. There are 8 older and 8 younger executives at Trevena Inc. The oldest executive at Trevena Inc is Anne Phillips, 66, who is the Independent Director.
What's Carrie Bourdow's mailing address?
Carrie's mailing address filed with the SEC is C/O TREVENA, INC., 955 CHESTERBROOK BLVD., SUITE 110, CHESTERBROOK, PA, 19087.
Insiders trading at Trevena Inc
Over the last 11 years, insiders at Trevena Inc have traded over $1,042,575 worth of Trevena Inc stock and bought 4,009,638 units worth $21,947,144 . The most active insiders traders include Adam Koppel, Terrance Mcguire e Partners Viii, L.P.Alta Par.... On average, Trevena Inc executives and independent directors trade stock every 90 days with the average trade being worth of $969,708. The most recent stock trade was executed by Barry Shin on 28 June 2022, trading 31,785 units of TRVN stock currently worth $13,032.
What does Trevena Inc do?
trevena, inc. is a clinical stage biopharmaceutical company that discovers, develops, and intends to commercialize innovative therapies that use a novel approach to target g protein coupled receptors, or gpcrs. we are dedicated to providing value to patients and healthcare providers by improving patient outcomes and reducing healthcare costs. we have identified four biased ligand drug candidates: trv130, an fda-designated breakthrough therapy, is currently in phase 3 testing for the intravenous treatment of acute moderate to severe pain; trv027 was evaluated in a phase 2b study for the treatment of acute heart failure; trv734 has completed phase 1 testing for oral treatment of acute and chronic pain; and trv250 is in preclinical development for the treatment of migraine. in addition, trevena has an early stage portfolio of drug discovery programs currently in lead optimization.
What does Trevena Inc's logo look like?
Complete history of Ms. Bourdow stock trades at Nabriva Therapeutics Plc, Trevena Inc e Sesen Bio
Trevena Inc executives and stock owners
Trevena Inc executives and other stock owners filed with the SEC include:
-
Maxine Gowen,
Director -
Carrie Bourdow,
President, Chief Executive Officer, Director -
Carrie L. Bourdow,
Pres, CEO & Director -
Mark Demitrack,
Senior Vice President and Chief Medical Officer -
Dr. Mark A. Demitrack,
Sr. VP & Chief Medical Officer -
Robert Yoder,
Senior Vice President and Chief Business Officer -
Dan Ferry,
IR Contact Officer -
Scott Applebaum,
Chief Legal and Compliance Officer and Senior Vice President of Regulatory Affairs -
Barbara Yanni,
Independent Director -
Anne Phillips,
Independent Director -
Jake Nunn,
Independent Director -
Julie McHugh,
Independent Director -
Michael Dougherty,
Independent Director -
Scott Braunstein,
Independent Director -
Barry Shin,
Chief Financial Officer, Senior Vice President -
Leon Moulder,
Independent Chairman of the Board -
Patricia M. Drake,
Chief Commercial Officer -
Robert T. Yoder,
Sr. VP, Chief Bus. Officer & Head of Commercial Operations -
Barry Shin,
Sr. VP & CFO -
Michael Catalano,
VP of Marketing -
Dr. Howard A. Rockman M.D.,
Scientific Founder, Consultant and Member of Scientific Advisory Board -
John P. Hamill,
VP Fin,Princ Fin&Acct Officer -
Marvin Johnson,
Director -
Michael W. Lark,
Sr. VP, Research & CSO -
Jason Raleigh Nunn,
Director -
Adam Koppel,
Director -
Yacoub Habib,
SVP, Bus Dev & Corp Planning -
Roberto Cuca,
Sr. VP and CFO -
David Soergel,
Sr. VP, Clinical Development -
John M Limongelli,
Sr. VP,General Counsel & Secy -
Jonathan Violin,
SVP-Scientific Affairs & IR -
David Geoghegan,
Sr. VP, Operations -
Partners Viii, L.P.Alta Par...,
-
Francois Nader,
Director -
Venture Management Co. V, L...,
-
Farah Champsi,
Director -
Robert Prachar,
Sr. VP, Corp. Strategy -
David F Solomon,
Director -
Rosamond Deegan,
Sr VP, Bus Dev & Operations -
Laboratories Holdings Ltd F...,
-
Terrance Mcguire,
Director -
Ventures Viii, L.P.Cavanaug...,
-
Venture Management Co. V, L...,
-
Patricia M. Drake,
SVP, Chief Commercial Officer -
Mark Corrigan,
Director